Contributions
Abstract: PB2297
Type: Publication Only
Session title: Platelet disorders
Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction.
Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.
Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.
Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.
Conclusion
Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.
Keyword(s): Antibody, Immune thrombocytopenia (ITP), Treatment
Abstract: PB2297
Type: Publication Only
Session title: Platelet disorders
Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction.
Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.
Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.
Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.
Conclusion
Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.
Keyword(s): Antibody, Immune thrombocytopenia (ITP), Treatment
Abstract: PB2297
Type: Publication Only
Session title: Platelet disorders
Background
Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction.
Aims
This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.
Methods
This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children's Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.
Results
When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.
Conclusion
Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.
Keyword(s): Antibody, Immune thrombocytopenia (ITP), Treatment